BRIEF-Axogen Announces FDA Approval Of Biologics License Application For Avance (Acellular Nerve Allograft–Arwx)

Reuters12-04

Dec 3 (Reuters) - AxoGen Inc AXGN.O:

AXOGEN ANNOUNCES FDA APPROVAL OF BIOLOGICS LICENSE APPLICATION FOR AVANCE® (ACELLULAR NERVE ALLOGRAFT–ARWX)

Source text: ID:nGNX6xflZR

Further company coverage: AXGN.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2588075285?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-04 09:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2588075285","market":"us","top_or_hot":-1,"title":"BRIEF-Axogen Announces FDA Approval Of Biologics License Application For Avance (Acellular Nerve Allograft–Arwx)","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Axogen Announces FDA Approval Of Biologics License Application For Avance (Acellular Nerve Allograft–Arwx)</title></head><body><p><span>Dec 3 (Reuters)</span><span> - </span>AxoGen Inc <span>AXGN.O</span>:</p><ul><li><p>AXOGEN ANNOUNCES FDA APPROVAL OF BIOLOGICS LICENSE APPLICATION FOR AVANCE® (ACELLULAR NERVE ALLOGRAFT–ARWX)</p></li></ul><p>Source text: <span>ID:nGNX6xflZR</span></p><p>Further company coverage: <span>AXGN.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Axogen Announces FDA Approval Of Biologics License Application For Avance (Acellular Nerve Allograft–Arwx)</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Axogen Announces FDA Approval Of Biologics License Application For Avance (Acellular Nerve Allograft–Arwx)\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-12-04 09:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Axogen Announces FDA Approval Of Biologics License Application For Avance (Acellular Nerve Allograft–Arwx)</title></head><body><p><span>Dec 3 (Reuters)</span><span> - </span>AxoGen Inc <span>AXGN.O</span>:</p><ul><li><p>AXOGEN ANNOUNCES FDA APPROVAL OF BIOLOGICS LICENSE APPLICATION FOR AVANCE® (ACELLULAR NERVE ALLOGRAFT–ARWX)</p></li></ul><p>Source text: <span>ID:nGNX6xflZR</span></p><p>Further company coverage: <span>AXGN.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"AXGN","symbol_name":"AxoGen Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251204:nFWN3XA001:1","article_id":"2588075285","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2588075285","pubTimestamp":1764810178,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Axogen Announces FDA Approval Of Biologics License Application For Avance (Acellular Nerve Allograft–Arwx)Dec 3 (Reuters) - AxoGen Inc AXGN.O:AXOGEN ANNOUNCES FDA APPROVAL OF BIOLOGICS LICENSE A","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"AXGN":"AxoGen Inc.","BK4082":"医疗保健设备"},"translate_title":"简介-Axogen宣布FDA批准Avance（脱细胞神经同种异体移植物-Arwx）的生物制剂许可申请","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AXGN":0.9},"content_text":"BRIEF-Axogen Announces FDA Approval Of Biologics License Application For Avance (Acellular Nerve Allograft–Arwx)Dec 3 (Reuters) - AxoGen Inc AXGN.O:AXOGEN ANNOUNCES FDA APPROVAL OF BIOLOGICS LICENSE APPLICATION FOR AVANCE® (ACELLULAR NERVE ALLOGRAFT–ARWX)Source text: ID:nGNX6xflZRFurther company coverage: AXGN.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.13","shortVersion":"4.35.13","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2588075285","isCrawlerRequest":true}